bèta
Trial Radar AI
De klinische studie NCT04458324 voor Ruggenmergletsels is recruterend. Bekijk de kaartweergave van de Klinische Studies Radar en de AI-ontdekkingstools voor alle details. Of stel hier een vraag.
Eén studie komt overeen met de filtercriteria
Kaartweergave

Hybrid Functional Electrical Stimulation Exercise to Prevent Cardiopulmonary Declines in High-level Spinal Cord Injury

Recruterend
Informatie over klinische studies is voornamelijk in het Engels beschikbaar. Trial Radar AI kan echter helpen! Klik op 'Leg studie uit' om de informatie over de studie te bekijken en te bespreken in de taal van uw keuze.
De klinische studie NCT04458324 onderzoekt preventie bij Ruggenmergletsels. Deze Fase 2 interventioneel-studie heeft de status recruterend. Het doel is om 70 deelnemers te includeren vanaf 22 december 2020. De studie wordt geleid door Spaulding Rehabilitation Hospital en de voltooiing is gepland op 31 juli 2026. Laatste update op ClinicalTrials.gov: 4 januari 2023.
Beknopte samenvatting
Over the past ten years, the Cardiovascular Research Laboratory at Spaulding has refined a unique form of exercise for those with spinal cord injuries (SCI). Functional Electrical Stimulation Row Training (FESRT) couples volitional arm and electrically controlled leg exercise, resulting in the benefits of large muscle mass exercise. However, despite the potential for enhancing aerobic capacity by training the denervated leg skeletal muscle via hybrid FES exercise, the inability to increase ventilation beyond limits set by high level SCI restricts aerobic capacity.

This research study will investigate two potential methods of improving ventilation in those with high-level SCI through a double-blind randomized trial. One method is non-invasive ventilation (NIV), which is an external breathing support machine. The second method is the use of Buspar, a drug, which has been used to treat respiratory dysfunction after SCI in rats and some human case reports.

In this study, participants will engage in a 6-month FES row training program while receiving either NIV or shamNIV and Buspar or placebo, and under study tests to evaluate cardiopulmonary health and fitness.

Uitgebreide beschrijving
Regular aerobic exercise with sufficient intensity can improve overall health, however daily energy expenditure is low in those with SCI, especially in those with high level lesions. The investigators have developed Functional Electrical Stimulation Row Training (FESRT) that couples volitional arm and electrically controlled leg exercise, increasing the active muscle and resulting in benefits of large muscle mass exercise. Despite the potential for enhancing aerobic capacity, those with high level lesions (T3 and above) have a remaining obstacle to attaining higher work capacities: a level of pulmonary muscle denervation. The investigators preliminary work suggests this limits the aerobic capacity that can be achieved with FESRT.

External ventilatory support could improve the ability to exercise train and hence enhance the adaptations to chronic exercise in high level SCI. Non invasive ventilation (NIV) during exercise training has been shown to improve gains in exercise capacity in those with similarly restrictive breathing. Therefore, the investigators hypothesize that the use of NIV during FESRT will reduce ventilatory limits to exercise, leading to increased aerobic capacity in high level SCI. In addition, pharmacologic treatments may augment respiratory control and improve exercise ventilatory responses. Buspirone can reverse respiratory abnormalities consequent to SCI in rats, and humans case reports suggest successful Buspirone treatment of respiratory dysfunction

Therefore, the investigators propose a double-blind 2x2 trial of 6 months of FESRT with NIV or Sham and Buspirone or Placebo in individuals with acute, high-level SCI. The investigators hypothesize that both NIV and Buspirone will improve ventilatory exercise responses and that combined treatment will have the greatest effect. This will result in greater improvements in aerobic capacity and concomitant increases in pulmonary function and reductions in cardiometabolic risk. This work proposes two approaches to overcome ventilatory limitations to exercise in high level SCI and allow for greater improvements in cardiopulmonary capacity - one that overcomes mechanical limitations of paralyzed pulmonary musculature and one that treats loss of serotonergic respiratory control, both of which may contribute to blunted ventilatory responses. The ultimate purpose of this research is to optimize exercise for a population that both needs and seeks the broad range of benefits that exercise can confer.

Officiële titel

Hybrid Functional Electrical Stimulation Exercise to Prevent Cardiopulmonary Declines in High-level Spinal Cord Injury

Aandoeningen
Ruggenmergletsels
Andere studie-ID's
  • 2020P001363
NCT-ID
Startdatum (Werkelijk)
2020-12-22
Laatste update geplaatst
2023-01-04
Verwachte einddatum
2026-07-31
Inschrijving (Geschat)
70
Studietype
Interventioneel
FASE
Fase 2
Status
Recruterend
Trefwoorden
Function Electrical Stimulation (FES)-Rowing
Primaire doel
Preventie
Toewijzing
Gerandomiseerd
Interventiemodel
Factorieel
Blindering
Dubbelblind
Armen / Interventies
Deelnemersgroep/StudiearmInterventie/Behandeling
ExperimenteelNIV + Buspar
Subjects will perform 6 months of FES-row-training while receiving NIV and taking Buspar.
Buspirone Hydrochloride
Subjects take 30 mg buspirone HCl twice a day for 6 months.
Noninvasive Ventilation (NIV)
The ventilator will be set in spontaneous mode with a ramp to reach a minimal pressure of 12 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
Functional Electrical Stimulation Row Training (FESRT)
Subjects participate in a supervised exercise training program 2-3 times/week for 6 months using an adapted indoor rower and FES.
Placebo-comparatorNIV + placebo
Subjects will perform 6 months of FES-row-training while receiving NIV and taking placebo.
Buspirone Placebo
Subjects take a placebo tablet twice a day for 6 months.
Noninvasive Ventilation (NIV)
The ventilator will be set in spontaneous mode with a ramp to reach a minimal pressure of 12 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
Functional Electrical Stimulation Row Training (FESRT)
Subjects participate in a supervised exercise training program 2-3 times/week for 6 months using an adapted indoor rower and FES.
Schijncomparatorsham NIV + Buspar
Subjects will perform 6 months of FES-row-training while receiving sham NIV and taking Buspar.
Buspirone Hydrochloride
Subjects take 30 mg buspirone HCl twice a day for 6 months.
Sham Non-invasive Ventilation (NIV)
The ventilator will be set in spontaneous mode with a ramp to reach a maximal pressure of 5 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
Functional Electrical Stimulation Row Training (FESRT)
Subjects participate in a supervised exercise training program 2-3 times/week for 6 months using an adapted indoor rower and FES.
Actieve comparatorsham NIV + placebo
Subjects will perform 6 months of FES-row-training while receiving sham NIV and taking placebo.
Buspirone Placebo
Subjects take a placebo tablet twice a day for 6 months.
Sham Non-invasive Ventilation (NIV)
The ventilator will be set in spontaneous mode with a ramp to reach a maximal pressure of 5 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
Functional Electrical Stimulation Row Training (FESRT)
Subjects participate in a supervised exercise training program 2-3 times/week for 6 months using an adapted indoor rower and FES.
Primaire uitkomst
UitkomstmaatBeschrijving van de uitkomstmaatTijdsbestek
Change in baseline aerobic exercise capacity
Participants perform incremental FES rowing exercise test to determine maximum oxygen consumption (VO2 peak)
Baseline, 3 months, 6 months
Change in baseline ventilation during exercise
Participants perform incremental FES rowing exercise test to determine ventilation during exercise (VE peak).
Baseline, 3 months, 6 months
Secundaire uitkomst
UitkomstmaatBeschrijving van de uitkomstmaatTijdsbestek
Change from baseline in glucoregulatory status
Blood will be taken via standard venipuncture to measure the homeostasis model assessment (HOMA) of insulin resistance.
Baseline, 3 months, 6 months
Change from baseline in glucoregulatory status
Blood will be taken via standard venipuncture to measure the quantitative insulin check index (QUICKI).
Baseline, 3 months, 6 months
Change from baseline in glucoregulatory status
Blood will be taken via standard venipuncture to measure hemoglobin A1c.
Baseline, 3 months, 6 months
Change from baseline in serum lipids
Blood will be taken via standard venipuncture to measure plasma total cholesterol.
Baseline, 3 months, 6 months
Change from baseline in serum lipids
Blood will be taken via standard venipuncture to measure low-density lipoprotein cholesterol.
Baseline, 3 months, 6 months
Change from baseline in serum lipids
Blood will be taken via standard venipuncture to measure high density apolipoprotein cholesterol.
Baseline, 3 months, 6 months
Change from baseline in serum lipids
Blood will be taken via standard venipuncture to measure triglycerides.
Baseline, 3 months, 6 months
Change from baseline in visceral adiposity
The investigators will use a 5th generation General Electric Healthcare dual x-ray absorptiometry (DXA) scanner for regional fat measurements, the DXA software can be used to define standard regions that will allow comparability of measurements throughout the study.
Baseline, 3 months, 6 months
Change in baseline forced vital capacity
Spirometry will be used to measure lung function, specifically forced vital capacity (FVC).
Baseline, 3 months, 6 months
Change in baseline maximal voluntary ventilation
Spirometry will be used to measure lung function, specifically maximal voluntary ventilation (MVV).
Baseline, 3 months, 6 months
Change in baseline forced expiratory capacity in the first second
Spirometry will be used to measure lung function, specifically forced expiratory capacity in the first second (FEV1).
Baseline, 3 months, 6 months
Geschiktheidscriteria

Leeftijd van deelnemers
Volwassene
Minimumleeftijd
18 Years
Geslachten die in aanmerking komen voor de studie
Allen
  • SCI outpatients aged 18-45 years
  • medically stable
  • body mass index 18.5-30 kg/m2 to include normal to overweight but not obese individuals
  • 3-months to 6-years post-injury
  • ASIA Scale A, B, or C injury at or above neurological level T4
  • able to follow directions
  • wheelchair users
  • leg muscles responsive to stimulation

  • BP >140/90 mmHg to exclude for hypertension (though rare in those with high level SCI)
  • current tobacco users
  • significant arrhythmias
  • coronary disease
  • diabetes
  • renal disease
  • cancer
  • epilepsy
  • current use of cardioactive medications (except medication to support blood pressure)
  • current grade 2 or greater pressure ulcers at relevant contact sites
  • other neurological disease
  • peripheral nerve compressions or rotator cuff tears that limit the ability to row
  • history of bleeding disorders
  • current use of buspirone
  • pregnancy
  • contraindications to Buspirone (taking MAO inhibitors, known hypersensitivity to buspirone, benzodiazepine dependence, akathisia, renal impairment, hepatic disease)
Spaulding Rehabilitation Hospital logoSpaulding Rehabilitation Hospital
Verantwoordelijke instantie
J. Andrew Taylor, Hoofdonderzoeker, Director, Cardiovascular Research Lab, Spaulding Rehabilitation Hospital
Centraal Contactpersoon
Contact: Glen Picard, MA, 617-758-5511, [email protected]
1 Studielocaties in 1 landen

Massachusetts

Spaulding Hospital Cambridge, Cambridge, Massachusetts, 02138, United States
Glen Picard, MA, Contact, 617-758-5511, [email protected]
Recruterend